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Effect of body mass index and alcohol consumption on liver
disease: analysis of data from two prospective cohort
studies
Carole L Hart, research fellow,1 David S Morrison, clinical senior lecturer in cancer epidemiology,1 G David
Batty, Wellcome trust fellow,2 Richard J Mitchell, professor of health and environment,1 George Davey Smith,
professor of clinical epidemiology3
ABSTRACT
Objective To investigate whether alcohol consumption
and raised bodymass index (BMI) act together to increase
risk of liver disease.
Design Analysis of data from prospective cohort studies.
Setting Scotland.
Participants Data were from two of the Midspan
prospective cohort studies (9559 men): “Main” study
1965-8, participants from workplaces across central belt
of Scotland, population of island of Tiree, and mainland
relatives, and “Collaborative” study, 1970-3, participants
from 27 workplaces in Glasgow, Clydebank, and
Grangemouth. Follow-up was to 31 December 2007
(median 29 years, range 0.13-42). We divided
participants into nine groups based on measures of body
mass index (BMI) (underweight/normal weight <25,
overweight 25 to <30, and obese ≥30) and alcohol
consumption (none, 1-14, and ≥15 units per week).
Main outcome measures Liver disease morbidity and
mortality.
Results 80 (0.8%)men diedwith liver disease as themain
cause and 146 (1.5%) with liver disease as any cause. In
the Collaborative study, 196men (3.3%) had liver disease
defined by a death, admission, or cancer registration. BMI
and alcohol consumption were strongly associated with
liver disease mortality in analyses adjusted for other
confounders (P=0.001 and P<0.0001 respectively).
Drinkers of 15 or more units per week in any BMI category
and obese drinkers had raised relative rates for all
definitions of liver disease, compared with underweight/
normal weight non-drinkers. Drinkers of 15 or more units
per week had adjusted relative rates for liver disease
mortality of 3.16 (95% confidence interval 1.28 to 7.8) for
underweight/normal weight men, 7.01 (3.02 to 16.3) for
overweight, and 18.9 (6.84 to 52.4) for obese men. The
relative rate for obese men who consumed 1-14 units per
week was 5.3 (1.36 to 20.7). The relative excess risk due
to interaction between BMI and alcohol consumption was
5.58 (1.09 to 10.1); synergy index=2.89 (1.29 to 6.47).
Conclusions Raised BMI and alcohol consumption are
both related to liver disease, with evidence of a supra-
additive interaction between the two. The occurrence of
both factors in the same populations should inform
health promotion and public health policies.
INTRODUCTION
Alcohol consumption is related to an increased risk of
liver disease. However, levels and patterns of alcohol
consumption do not fully explain the rises in liver dis-
ease mortality that have occurred in some countries.1-4
Evidence has been accumulating of associations
between obesity and liver disease, with strong relations
shown in a meta-analysis of studies of liver cancer,5 a
cohort study on cirrhosis related death or
hospitalisation,6 and a cohort study of all mortality
from liver disease in male civil servants.7 We recently
showed with data from three of the Midspan studies
that body mass index (BMI) was strongly related to
liver disease inmen,with someevidenceof a relation in
women.8
The international epidemicof obesity9 raises the pos-
sibility that heavy alcohol intake and obesity could be
working in unison to elevate risk of liver disease. The
mechanisms by which alcohol and obesity affect the
liver are not fully understood but biochemical and
pathological evidence suggests that commonpathways
exist.10 In moderate drinkers alanine aminotransfer-
ase, which indicates hepatic damage, is raised to a
greater extent in those with higher BMI,11 and alco-
holic and non-alcoholic fatty liver disease are patholo-
gically similar.12 The high prevalence of people who
consume excess alcohol and are overweight or obese
means that a better understanding of their prognosis is
of clinical importance. Additionally, as liver disease is
often advanced when diagnosed, primary prevention
is crucial to reducing the burden.
We investigated whether alcohol and obesity could
be acting together to increase the risk of liver disease.
METHODS
The first Midspan study was known as “Main”, and
included employees in several workplaces across the
central belt of Scotland, the population of the island
of Tiree, and their relatives on the mainland.13 14 The
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study was conducted between 1965 and 1968 with par-
ticipants aged from 14 to 92 years at screening. The
second Midspan study, known as the Collaborative
study, included employees aged 21-75 years from 27
workplaces in Glasgow, Clydebank, and Grange-
mouth between 1970 and 1973.15 Only men were
included in the current analysis because numbers of
women and of events in women in the two studies
were small.
The studies consisted of a self completed question-
naire followed by a screening examination at a study
clinic. The questionnaire included questions about
usual weekly consumption of beer, spirits, and wine,
occupation, smokinghabit, bronchitis, angina, anddia-
betes. At the screening examination measurements
were made for blood pressure and forced expiratory
volume in 1 second (FEV1) and an electrocardiogram
was done. Height and weight were reported in the
questionnaire in the Main study, but were measured
at the clinic in the Collaborative study.
The question on alcohol consumption asked how
many nips of spirits, pints of beer, and bottles of wine
were usually consumed each week. Responses were
converted to units of alcohol appropriate at the time
(one unit was equal to half pint of beer, a measure of
spirits, or a sixth of a bottle ofwine) anddivided into six
categories (none, 1-7, 8-14, 15-21, 22-34, or ≥35
units).16 A unit of alcohol in theUK is equal to 8 g etha-
nol. Social class was derived from occupation accord-
ing to the relevant version of the General Register
Office Classification of Occupations (1960 for
Main,17 1966 for Collaborative18). Social class was
graded in six categories from I (professional) to V
(unskilled), with III subdivided into non-manual or
manual. Smoking was defined by number of cigarettes
smoked per day for current and former smokers, with
an additional term to denote former smokers. Bronchi-
tis was defined by responses to the Medical Research
Council bronchitis questionnaire19 and angina accord-
ing to the Rose questionnaire.20 Presence of diabetes
was taken as a positive response to a question asking
if the participant had diabetes. At the screening exam-
ination, blood pressure was measured with a London
School of Hygiene sphygmomanometer with the par-
ticipant seated. FEV1 was measured with a Vitalo-
graph spirometer (Garthur (London), Buckingham,
UK) with the participant standing. Ischaemia on elec-
trocardiogram was defined as any of Minnesota codes
1.1-1.3, 4.1-4.4, 5.1-5.3, and 7.1.21 BMI was calculated
fromweight in kg divided by height squared in m2 and
categorised according to WHO categories under-
weight (<18.5), normal weight (18.5 to <25), over-
weight (25 to <30), and obese (≥30).
Follow-up after screening was by flagging with the
NHSCentral Register.Dates of deaths and their causes
as well as embarkations from the UK are notified
monthly to the Midspan team. In addition, the Colla-
borative study participants have been linked with the
Scottish Morbidity Records (SMR) data. The Privacy
Advisory Committee of NHS Scotland Information
Services gave permission for the linked data to be
used in the current study. Acute hospital discharges
(SMR1) and cancer registrations (SMR6) were used
from 1972 to 31 December 2007. Any SMR records
occurring before each individual’s screening date
were excluded.
Liver disease was defined as ICD9 codes 155 and
570-573, and ICD10 codes C22 and K70-K77, which
include liver diseases and (primary) liver cancer. Mor-
tality from liver disease was defined as having one of
these causes as the underlying (main) cause of death.
Mortality with liver disease mentioned in any position
of the causes of death was also investigated. Follow-up
was from the date of screening to the date of death, date
of embarkation, or 31 December 2007 (median
29 years, maximum 42 years).
A further analysis defined having liver disease as the
participant having an SMR1 with any of the diagnosis
codes for liver disease, or an SMR6 for liver cancer, or
liver disease mentioned in any of the causes of death.
Table 1 | Liver disease mortality by BMI category
BMI category
P RR per SD increase in BMI*
Underweight/normal
weight (n=5033)
Overweight
(n=4000)
Obese
(n=526)
Liver disease as main cause of death†
Number of deaths 29 39 12 – –
RR1 1 1.78
(1.10 to 2.90)
5.07
(2.57 to 10.0)
<0.0001 1.48
(1.20 to 1.81)
RR2 1 1.79
(1.10 to 2.91)
4.68
(2.33 to 9.42)
0.001 1.44
(1.17 to 1.78)
Liver disease in any position‡
Number of deaths 54 74 18 – –
RR1 1 1.75
(1.23 to 2.49)
3.97
(2.32 to 6.79)
<0.0001 1.46
(1.26 to 1.70)
RR2 1 1.74
(1.22 to 2.48)
3.45
(1.98 to 6.01)
<0.0001 1.41
(1.21 to 1.65)
RR=relative rate (95% CI), RR1= relative rate adjusted for age and study, RR2= relative rate adjusted for age, study, social class, smoking, systolic
blood pressure, height, bronchitis, FEV1, angina, ischaemia on electrocardiogram, and diabetes.
*1 SD BMI=3.07.
†P for interaction between studies=0.09.
‡P for interaction between studies=0.31.
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Follow-up was to the date of the first occurrence of the
SMR1, SMR6, death, embarkation, or 31 December
2007. This analysis was only possible for the Colla-
borative study because SMR data were not available
for the Main study.
The Main study included 3750 men and the Colla-
borative study 6022, giving a total of 9772. The 156
men who took part in both studies were included
only once in the joint analysis. Data from the Colla-
borative study were used in preference to those of the
Main study because BMI was measured in the Colla-
borative study, rather than self-reported. The 31 Main
study men who were younger than 18 at screening
were excluded because they would not have achieved
an adult BMI. Other exclusions were five Collabora-
tive men who were lost to follow-up and 24Main men
and one Collaborative man with missing BMI. Of the
24 Main men with missing BMI, four were duplicates
and their data were available from the Collaborative
study. In total 9559 participants were included in the
study. The analyses using just the Collaborative study
data included 6016 participants.
Statistical analysis
All analyses were done with Stata (release 10). The
underweight category included 74 participants (27
Main, 47 Collaborative). Since only one death from
liver disease occurred in the underweight category it
was combined with the normal weight category. Sub-
group analyses were also done after excluding under-
weight participants. Men known to have left the UK
(Main 7, Collaborative 50) were censored at the date
of embarkation. Cox proportional hazards models
were used to obtain relative rates of mortality from
liver disease (or having liver disease) by BMI category
and for one standard deviation (SD) increase in BMI.
The baseline category was taken as the underweight/
normal weight category. Similar analyses were done
by alcohol category and per unit increase in weekly
consumption, with non-drinkers as the baseline.
Relative rates were also obtained for BMI and alcohol
consumption combined. For this analysis, the alcohol
categories were regrouped into three categories of
none, 1-14, and ≥15 units per week, so constructing
nine groups of BMI and alcohol. The underweight/
normal weight non-drinkers were used as the baseline
category. Proportional hazards assumptions were
checked using Schoenfeld residuals. Tests for inter-
action with study did not provide strong evidence of
difference between theMain andCollaborative studies
(P values shown in tables).
Table 2 | Liver disease mortality by alcohol consumption
Units of alcohol consumed per week
P
RR per unit
increase*0 (n=3355) 1-7 (n=1817) 8-14 (n=1766) 15-21 (n=1017) 22-34 (n=942) ≥35 (n=662)
Liver disease as main cause of death†
Deaths 10 9 7 16 19 19 – –
RR1 1 1.62
(0.65 to 3.99)
1.33
(0.51 to 3.51)
5.61
(2.54 to 12.4)
7.35
(3.40 to 15.9)
11.5
(5.31 to 25.0)
<0.0001 1.03
(1.02 to 1.03)
RR2 1 1.50
(0.60 to 3.70)
1.24
(0.47 to 3.27)
5.17
(2.32 to 11.5)
6.81
(3.10 to 14.9)
10.5
(4.74 to 23.3)
<0.0001 1.03
(1.02 to 1.03)
Liver disease in any position‡
Deaths 19 18 22 23 33 31 – –
RR1 1 1.66
(0.87 to 3.17)
2.17
(1.17 to 4.01)
4.22
(2.29 to 7.76)
6.56
(3.72 to 11.6)
9.58
(5.38 to 17.1)
<0.0001 1.02
(1.02 to 1.03)
RR2 1 1.59
(0.83 to 3.03)
2.04
(1.10 to 3.78)
3.75
(2.03 to 6.95)
5.90
(3.31 to 10.5)
8.40
(4.64 to 15.2)
<0.0001 1.02
(1.01 to 1.03)
RR=relative rate (95% CI), RR1= relative rate adjusted for age and study, RR2= relative rate adjusted for age, study, social class, smoking, height,
bronchitis, FEV1, angina, ischaemia on electrocardiogram, and diabetes.
*Excluding non-drinkers.
†P for interaction between studies=0.93.
‡P for interaction between studies=0.87.
Table 3 | Liver disease mortality by BMI and alcohol
consumption
Drinking status (units per week)
0 1-14 ≥15
Underweight/normal weight
Number of men 1749 1950 1334
Number of deaths 7 6 16
RR1 1 0.77
(0.26 to 2.31)
3.43
(1.41 to 8.37)
RR2 1 0.72
(0.24 to 2.14)
3.16
(1.28 to 7.80)
Overweight
Number of men 1414 1465 1121
Number of deaths 3 7 29
RR1 0.58
(0.15 to 2.24)
1.26
(0.44 to 3.60)
7.35
(3.20 to 16.9)
RR2 0.60
(0.16 to 2.33)
1.21
(0.42 to 3.48)
7.01
(3.02 to 16.3)
Obese
Number of men 192 168 166
Number of deaths 0 3 9
RR1 – 5.44
(1.40 to 21.1)
18.7
(6.91 to 50.7)
RR2 – 5.30
(1.36 to 20.7)
18.9
(6.84 to 52.4)
RR=relative rate (95% CI), RR1= relative rate adjusted for age and study,
RR2= relative rate adjusted for age, study, social class, smoking, height,
bronchitis, FEV1, angina, ischaemia on electrocardiogram, and diabetes.
RESEARCH
BMJ | ONLINE FIRST | bmj.com page 3 of 7
The proportional hazards models were first adjusted
for age at screening and study, and were then adjusted
for other risk factors (social class, smoking, systolic
blood pressure, height, bronchitis, FEV1, angina,
ischaemia on electrocardiogram, and diabetes). Miss-
ing values of these risk factorswere substitutedwith the
study-specificmeans ormodes.Adjustment for systolic
blood pressure was not included in the analyses with
alcohol consumption because of strong evidence that
alcohol intake increases blood pressure.22 Such adjust-
ment would have been for a variable on the causal
pathway between alcohol and mortality.
The mortality analyses were repeated after exclud-
ing deaths and embarkations in the first five years of
follow-up and the first 10 years of follow-up, since par-
ticipants with pre-existing liver diseasemight have had
lower thanusualBMIs at screeningor couldhave given
up alcohol due to ill health and therefore appeared in
the non-drinking category. These factors could have
led to underestimation of the association of BMI or
alcohol with liver disease mortality.
To investigate any supra-additive (sometimes called
biological23 or causal24) interaction between BMI and
alcohol consumption, the relative excess risk due to
interaction and the synergy index were obtained,
using the methodology of Andersson et al.25 The
hypothesis was that the combined effect of high BMI
and alcohol would be greater than the simple additive
effects of each factor separately. In this case the relative
excess risk due to interaction would be greater than
zero and the synergy index would be greater than
one. For this analysis, high BMI was defined as being
overweight or obese, and high alcohol consumption
defined as drinking 15 or more units per week.
RESULTS
The mean age at screening of the 9559 men was 47.
3 years (SD 9.55). Just under half the men were either
overweight (42%) or obese (6%) (table 1). Eighty men
(0.8%) died with liver disease as the main cause of
death, and 146 (1.5%) died with liver disease men-
tioned in any of the causes of death. BMI was strongly
associated with death from liver disease defined as the
main cause (relative rate adjusted for age and study per
SD increase in BMI=1.48, 95% confidence interval
(CI) 1.20 to 1.81) or as any of the causes (1.46, 1.26 to
1.70). Overweight men had higher relative rates than
underweight/normal weight men, and obese men had
very high relative rates: fivefold increase for liver dis-
ease as the main cause and nearly fourfold increase for
liver disease as any cause. Adjustment for risk factors
caused a little attenuation.
The men reported consuming an average of 16.56
units of alcohol per week. The type of alcohol con-
sumedwas predominantly beer (68.5%of units), spirits
accounted for 28.3%, and wine consumption was very
low (3.2%).While 35% of men reported consuming no
alcohol, 27% reported consuming 15 ormore units per
week (table 2). Very strong relations were noted
between alcohol consumption and liver disease mor-
tality, with the increase starting with drinkers of 15-21
units for liver disease as the main cause, and with 8-14
units for liver disease as any cause. Adjustment for risk
factors caused some attenuation but the strong rela-
tions remained.
With the men divided into nine groups by BMI and
drinking status, high relative rates for liver disease
mortality were seen for drinkers of 15 or more units
per week in any BMI category, and in obese drinkers,
compared with underweight/normal weight non-drin-
kers (table 3). With no deaths from liver disease in the
obese non-drinkers, no risk information could be
obtained from the model for that group. For drinkers
of 1-14 units and 15 ormore units risk increased across
the BMI groups. Similarly within the overweight and
obese groups risk increased by amount drunk. Obese
drinkers of 15 or more units had the highest relative
Table 4 | Liver disease mentioned as any cause of death by
BMI and alcohol consumption
Drinking status (units per week)
0 1-14 ≥15
Underweight/normal weight
Number of men 1749 1950 1334
Number of deaths 11 15 28
RR1 1 1.21
(0.55 to 2.64)
3.79
(1.88 to 7.63)
RR2 1 1.14
(0.52 to 2.49)
3.32
(1.63 to 6.74)
Overweight
Number of men 1414 1465 1121
Number of deaths 8 20 46
RR1 0.95
(0.38 to 2.37)
2.17
(1.04 to 4.53)
7.02
(3.62 to 13.6)
RR2 0.97
(0.39 to 2.41)
2.09
(1.0 to 4.37)
6.39
(3.27 to 12.5)
Obese
Number of men 192 168 166
Number of deaths 0 5 13
RR1 – 5.57
(1.93 to 16.1)
16.2
(7.22 to 36.4)
RR2 – 5.01
(1.73 to 14.5)
14.3
(6.27 to 32.7)
RR=relative rate (95% CI), RR1= relative rate adjusted for age and study,
RR2= relative rate adjusted for age, study, social class, smoking, height,
bronchitis, FEV1, angina, ischaemia on electrocardiogram, and diabetes.
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rate (18.7, 95% CI 6.91 to 50.7). Adjustment for risk
factors had a small effect. Similar findings were noted
for liver disease as any cause of death and overweight
drinkers of 1-14 units had elevated relative rates
(table 4).
In the Collaborative study 196 men (3.3%) had
either a death or admission with any mention of liver
disease, or a cancer registration for liver cancer
(table 5). Results were similar to those for mortality
only, with narrower confidence intervals because of
the larger number of events. Obese men who drank
15 or more units had the highest relative rates of 10.5
(95% CI 4.80 to 23.1) compared with underweight/
normal weight non-drinking men.
We found strong evidence of a supra-additive inter-
action between BMI and alcohol consumption. The
figure shows the excess risks due to BMI, alcohol con-
sumption, and their interaction in an analysis of liver
disease mortality (main cause) adjusted for all risk fac-
tors. The excess risk due to BMI was small compared
with that due to alcohol, but the relative excess risk due
to interaction was large (5.58, 95% CI 1.09 to 10.1).
The synergy index was 2.89 (1.29 to 6.47). The effect
of the combination of high BMI and alcohol was
clearly greater than the additive effect of the two sepa-
rately; being both overweight or obese and consuming
15 or more units per week of alcohol led to a greater
risk of dying of liver disease.
Analyses excluding underweight and analyses
excluding deaths in the first five or first 10 years
yielded results similar to those reported here (see sup-
plementary tables).
DISCUSSION
Principal findings
In this prospective cohort study we investigated the
joint effects of BMI and alcohol consumption on liver
disease. Both factors were related to liver disease and,
more importantly, we noted a supra-additive inter-
action between the two. There are plausible biological
mechanisms for this interaction. Obesity leads to stea-
tohepatitis through its effects on hepatic insulin sensi-
tivity and the lipid solubility of alcohol makes adipose
tissue a target for its effects.10 Conversely, alcoholic
fatty liver induces peripheral insulin resistance and
therefore promotes obesity. This may be mediated
through the appetite enhancing effect of alcohol26 or
failure to compensate for the extra energy obtained
from alcohol by decreasing other food intake.27
Strengths and limitations of the study
The study was large, withmore than 9000 participants,
and had a long follow-up period of up to 42 years. BMI
was measured at screening, whereas in cross sectional
or clinical studies it is not possible to determine
whether raised BMI preceded (and might increase
risk of) liver disease or was caused by it. Reporting of
alcohol consumption at screeningmeant that therewas
no recall bias. The alcohol data were reliable and simi-
lar to levels seen in a Scottish study in 1972.28 29 The
study also benefited from the availability of the linked
Scottish hospital discharge data and cancer registration
data. Another advantage was the availability of other
confounders for adjustment in the models.
Limitationswere that BMI and alcohol consumption
could have changed in the follow-up period. This is a
disadvantage of prospective cohort studies that can
only be overcome by repeating surveys several times
over the whole follow-up period. Alcohol consump-
tion tends to decrease as people age,30 although since
alcohol consumption increased in the wider popula-
tion in the follow-up period, some participants might
have increased their consumption after screening. It is
not possible to reliably ascertain how these counterba-
lancing tendencies will affect our estimates of precise
levels at which alcohol—and BMI, which has also
increased over time, but can decrease in individuals
at older ages—act together synergistically to influence
liver disease risk. However, these changes are unlikely
to have affected the existence of the interaction we
report.
Weight and height were self-reported in the Main
study but measured in the Collaborative study. This
difference is unlikely to have affected our conclusions
since similar results were obtained when the studies
were analysed separately. If self-reported heights
were overestimated and self-reported weights were
underestimated in the Main study, as is seen in some
studies, then BMI would have been underestimated.31
Table 5 | Liver disease ascertained by any position on the
death certification, any position on SMR1, or cancer
registration by BMI and alcohol for men in the Collaborative
study only
Drinking status (units per week)
0 1-14 ≥15
Underweight/normal weight
Number of men 927 1191 849
Number with liver
disease
12 25 36
RR1 1 1.68
(0.84 to 3.34)
4.05
(2.11 to 7.79)
RR2 1 1.62
(0.81 to 3.23)
3.62
(1.87 to 7.01)
Overweight
Number of men 845 996 849
Number with liver
disease
13 24 67
RR1 1.25
(0.57 to 2.74)
1.90
(0.95 to 3.81)
7.33
(3.96 to 13.6)
RR2 1.27
(0.58 to 2.78)
1.86
(0.93 to 3.73)
6.86
(3.68 to 12.8)
Obese
Number of men 120 107 132
Number with liver
disease
0 6 13
RR1 – 4.96
(1.86 to 13.2)
10.5
(4.80 to 23.1)
RR2 – 4.50
(1.68 to 12.0)
9.73
(4.38 to 21.6)
RR=relative rate (95% CI), RR1= relative rate adjusted for age, RR2=
relative rate adjusted for age, social class, smoking, height, bronchitis,
FEV1, angina, ischaemia on electrocardiogram, and diabetes.
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However, a different study of Scottishmen andwomen
showed that both height and weight were underesti-
mated, which resulted in a very slightly overestimated
BMI.31Waist and hip measurements were not taken in
the studies, so alternative measures of obesity could
not be used. Alcohol consumption was limited to
units per week as no data were available on frequency
of drinking or binge drinking. However, a small clini-
cal study suggested that daily heavy drinking rather
than less frequent binge drinking drove alcohol-related
liver disease risk.32 Women could not be included
because of small numbers and lack of events. A final
limitation was that no clinical measurements of liver
function were recorded in the study.
Other studies
A study in China found that abnormal levels of serum
liver enzymes (alanine aminotransferase and serum γ-
glutamyltranspeptidase) were more likely in drinkers
of 40 g or more of alcohol per day who were also over-
weight or obese, compared with either single factor
alone or neither factor.33 A cross-sectional study in
Australia found that BMI was strongly associated
with alanine aminotransferase.34 Obese participants
who were heavy drinkers had the highest alanine ami-
notransferase levels and obesity accounted for half of
the raised levels, compared with excess alcohol, which
accounted for under 10%. This finding seems contrary
to our results, in which alcohol had a greater effect than
BMI on liver disease, although this discrepancy might
reflect differences between countries.
In a study of patients with alcoholism or alcoholic
liver disease, excess weight in the previous 10 years
was an independent risk factor for the development
of alcoholic cirrhosis, acute alcoholic hepatitis, and
steatosis.35 Excess weight was defined as BMI 27 or
greater in men and 25 or greater in women. A later
study of similar patients found that BMI in the year
preceding hospitalisation (before symptoms appeared)
was an independent risk factor for fibrosis.36 A small
cross-sectional population study in Italy found that
alcohol and obesity were both associated with hepatic
steatosis, and being both a heavy drinker and obese led
to a higher risk of hepatic steatosis.37 In a small clinical
case-control study in the United States, Marrero found
positive interactions between alcohol consumption
and obesity in a study of hepatocellular carcinoma.38
However, in that study, BMI was measured when the
patient was already ill, so values might not have
reflected their usual weights. Prospective cohort stu-
dies have an advantage over clinical studies since
BMI will generally reflect a healthy weight.
Apopulation based cohort study in theUnited States
found a strong association between obesity and cirrho-
sis related death or hospitalisation in non-drinkers of
alcohol, a weaker association in alcohol drinkers of up
to 0.3 drinks per day, and no association in drinkers of
more than 0.3 drinks per day.6 Drinkers, however, did
have higher rates of death or hospitalisation than non-
drinkers.
As the participants in the present study were from
general and working populations, the results may be
generalisable to other populations. However, since
the majority of the men were from working popula-
tions—and therefore healthier on average than general
populations—the results might underestimate the
absolute risk of liver disease, although the relative
risks are likely to be generalisable to populations
from similar contexts. The findings need to be vali-
dated in other large cohort studies and in women.
Implications
Our findings have important clinical and public health
implications. New perspectives on the risk of liver dis-
ease may need to be considered for people who are
overweight and consume alcohol and lower, BMI spe-
cific “safe” limits of alcohol consumption may need to
be defined. Liver disease is often advanced when it is
diagnosed and therefore early clinical intervention and
primary prevention are both important. In public
health terms, the interaction is of importance because
it indicates that clustering of BMI and alcohol intake
would generate more disease in a population than if
they were not associated with each other.39 Further-
more, simultaneous increases in both alcohol intake
and obesity levels would generate higher levels and
more rapid increases in liver disease than predicted
from effects of each factor separately. From a public
health perspective, strategies to jointly reduce both
alcohol consumption and obesity among high risk
populations with both risk factors are likely to produce
much greater reductions in liver disease than through
initiatives directed at each group separately. Reducing
alcohol consumption may also be an effective element
in weight reduction strategies. Health education is
needed to highlight the combined risks of BMI and
alcohol on liver disease. Further preventive efforts
are also needed to limit the affordability and availabil-
ity of alcohol and to increase physical activity.
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